25/08/2026 Spyre Therapeutics announced topline results from the RA Sub-study of the Phase 2 SKYWAY trial of SPY072 Spyre Therapeutics announced topline results from the RA Sub-study of the Phase 2 SKYWAY trial of SPY072 (Ref) Spyre Therapeutics announced topline results from the rheumatoid arthritis (RA) sub-study of its Phase 2, SKYWAY-RD/ NCT07148414 basket trial evaluating SPY072 (Anti-TL1A) in rheumatic diseases. Both the doses of SPY072 demonstrated statistically signif